Novo Nordisk seeks FDA approval of new insulin preparation  

2002.12.09
Novo Nordisk has submitted an application for its new long-acting insulin analogue NN304 to the US Food and Drug Administration

Novo Nordisk has submitted an application for its new long-acting insulin analogue NN304 (insulin determir) to the US Food and Drug Administration (FDA). NN304 is designed to provide a smoother basal insulin profile with less day-to-day variation than conventional preparations. Novo Nordisk has already submitted an application to the European Medicines Evaluation Agency (EMEA) for the approval of NN304 in Europe.

 

Headquartered in Zealand, Denmark, Novo Nordisk is the world leader in diabetes care. The company employs around 18,000 people in 68 countries and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London.

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×